Drug developer Otonomy Inc. said its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.
Industry Veteran to Lead High Growth Technology Team JERSEY CITY, N.J., Jan. 5, 2017 /PRNewswire/ — TrialScope, the global leader in managed compliance solutions for clinical trial disclosure, today announced that the Board of Directors have appointed Mark Heinold as chief executive officer. Mr. Heinold joins TrialScope with over […]
Pieris, based in Boston, and Servier Forge, located in Suresnes, France, signed a broad collaboration deal focused on immuno-oncology.
Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.
Arena Pharmaceuticals is shedding some unwanted weight. The company is selling its weight-loss drug Belviq to Eisai Co. Ltd., which has marketing rights to Belviq throughout much of the world.
President-elect Donald Trump has made repealing President Barack Obama’s signature healthcare law the “first order of business” and intends a smooth transition to a “market-based” medical insurance system, said Vice President-elect Mike Pence.
Another Novartis AG office has been raided by authorities in connection to bribery allegations. This time authorities in Greece searched electronic data and files following the submission of media reports to that nation’s justice department.
Gilead Sciences has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology.
Nivalis Therapeutics announced that it is evaluating “strategic alternatives,” which may include the possibility of an acquisition, merger or other strategic transaction.
In September 2016, Allergan’s Chief Executive Officer Brent Saunders publicly vowed to keep price increases on the company’s drugs under 10 percent in 2017. Saunders kept his word. The Irish company announced nine older drugs would see price increases of 9 to 9.5 percent–staying under that 10 percent mark.
A U.S. judge almost halved the award in a December 2016 jury verdict that ordered J&J and DePuy Orthopaedics to pay $1+ billion to plaintiffs in six lawsuits.
A federal judge refused to throw out a court verdict upholding two Amgen patents related to its cholesterol drug, a defeat for Sanofi and Regeneron Pharmaceuticals, which make a rival drug.
More than 10 million U.S. children do not live near a pediatric anesthesiologist, a doctor who specializes in sedating children during surgery, according to a recent study.
Inotek Pharmaceuticals Corp. said its experimental glaucoma treatment failed a late-stage study, citing a stronger-than-expected placebo effect.
Versant Ventures closed on its newest fund, Versant Venture Capital VI, with $400 million it plans to invest in 20 to 25 biotechnology companies in the U.S., Canada and Europe. The first investment is expected in the first quarter of 2017.
In the first half of 2016, investors were watching the Pfizer-Allergan merger deal, which was scuttled in April by the U.S. Treasury Department. Part of the fascination, besides the fact it would have created the largest pharmaceutical company in the world, was over how in about seven years Allergan’s CEO Brent Saunders had gone from heading the consumer health division at Schering-Plough to being the chief-executive-in-waiting for the biggest pharma company on the planet.
There are plenty of “brand name” biotech companies out there that everyone interested in biopharma knows about — Shire, Gilead Sciences, Genentech, Biogen and so on — but there are several smaller biotech companies that investors may not have heard of that are worth checking out. Keith Speights, writing for The Motley Fool, takes a look at three.
Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.
2016 turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45.